HO-1 modified mesenchymal stem cells modulate MMPs/TIMPs system and adverse remodeling in infarcted myocardium

Tissue and Cell

Volumn 42, Issue 4, 2010, Pages 217-222

  Shu, Tao ^a   Zeng, Bin ^b   Ren, Xiaofeng ^c   Li, Yanglin ^d  

^a SICHUAN UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^d Department of ENT Sha Yang people's Hospital ^*  (China)

Author keywords

Extracellular matrix; Heme oxygenase 1; Mesenchymal stem cells; Myocardial infarction; Remodeling

Indexed keywords

GELATINASE A; GELATINASE B; HEME OXYGENASE 1; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME REGULATION; EXTRACELLULAR MATRIX; HEART LEFT VENTRICLE RELAXATION; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE REMODELING; IMMUNOFLUORESCENCE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; UPREGULATION;

RATTUS;

EID: 77955925294     PISSN: 00408166     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tice.2010.04.004     Document Type: Article

References (29)

1. Angoulvant D., Fazel S., Weisel R.D., Lai T.Y., Fedak P.W., Chen L., Rafati S., Seneviratne C.K., Degousee N., Li R.K. Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3-deficient mice. J. Thorac. Cardiovasc. Surg. 2009, 137:471-480.
2. Brower G.L., Gardner J.D., Forman M.F., Murray D.B., Voloshenyuk T., Levick S.P., Janicki J.S. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur. J. Cardiothorac. Surg. 2006, 30:604-610.
3. Campo G.M., Avenoso A., Campo S., D'Ascola A., Ferlazzo A.M., Samà D., Calatroni A. Purified human chondroitin-4-sulfate reduced MMP/TIMP imbalance induced by iron plus ascorbate in human fibroblast cultures. Cell Biol. Int. 2006, 30:21-30.
4. Di Donato M., Dabic P., Castelvecchio S., Santambrogio C., Brankovic J., Collarini L., Joussef T., Frigiola A., Buckberg G., Menicanti L., Restore Group Left ventricular geometry in normal and post-anterior myocardial infarction patients: sphericity index and new conicity index comparisons. Eur. J. Cardiothorac. Surg. 2006, 29:225-230.
5. Fedak P.W., Smookler D.S., Kassiri Z., Ohno N., Leco K.J., Verma S., Matson K.L., Waston K.L., Hojilla C.V., Cruz W., Weisel R.D., Li R.K., Khokha R. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 2004, 110:2401-2409.
6. Fedak P.W., Szmitko P.E., Weisel R.D., Altamentova S.M., Nili N., Ohno N., Verma S., Fazel S., Strauss B.H., Li R.K. Cell transplantation preserves matrix homeostasis: a novel paracrine mechanism. J. Thorac. Cardiovasc. Surg. 2005, 130:1430-1439.
7. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res. 2002, 53:31-47.
8. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., Mu H., Melo L.G., Pratt R.E., Ingwall J.S., Dzau V.J. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006, 20:661-669.
9. Hayashidani S., Tsutsui H., Ikeuchi M., Shiomi T., Matsusaka H., Kubota T., Imanaka-Yoshida K., Itoh T., Takeshita A. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:1229-1235.
10. Juan S.H., Lee T.S., Tseng K.W., Liou J.Y., Shyue S.K., Wu K.K., Chau L.Y. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001, 104:1519-1525.
11. Kadokami T., Frye C., Lemster B., Wagner C.L., Feldman A.M., McTiernan C.F. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 2001, 104:1094-1097.
12. Li Y.Y., McTiernan C.F., Feldman A.M. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc. Res. 1999, 42:162-172.
13. Lin C.W., Shen S.C., Hou W.C., Yang L.Y., Chen Y.C. Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. Mol. Cancer Ther. 2008, 7:1195-1206.
14. Lindsey M.L., Gannon J., Aikawa M., Schoen F.J., Rabkin E., Lopresti-Morrow L., Crawford J., Black S., Libby P., Mitchell P.G., Lee R.T. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002, 105:753-758.
15. Lindsey M., Wedin K., Brown M.D., Keller C., Evans A.J., Smolen J., Bossen R.D., Michael L., Entman M. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001, 103:2181-2187.
16. Liu X., Pachori A.S., Ward C.A., Davis J.P., Gnecchi M., Kong D., Zhang L., Murduck J., Yet S.F., Perrella M.A., Pratt R.E., Dzau V.J., Melo L.G. Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J. 2006, 20:207-216.
17. Matsumura S., Iwanaga S., Mochizuki S., Okamoto H., Ogawa S., Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J. Clin. Invest. 2005, 115:599-609.
18. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006, 69:562-573.
19. Pauschinger M., Chandrasekharan K., Schultheiss H.P. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail. Rev. 2004, 9:21-31.
20. Peterson J.T., Li H., Dillon L., Bryant J.W. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc. Res. 2000, 46:307-315.
21. Polyakova V., Hein S., Kostin S., Ziegelhoeffer T., Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J. Am. Coll. Cardiol. 2004, 44:1609-1618.
22. Roten L., Nemoto S., Simsic J., Coker M.L., Rao V., Baicu S., Defreyte G., Soloway P.J., Zile M.R., Spinale F.G. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J. Mol. Cell. Cardiol. 2000, 32:109-120.
23. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 2002, 90:520-530.
24. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley A.J., Spinale F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998, 97:1708-1715.
25. Vanhoutte D., Schellings M., Pinto Y., Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc. Res. 2006, 69:604-613.
26. Whiteside E.J., Jackson M.M., Herington A.C., Edwards D.R., Harvey M.B. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 are key regulators of extracellular matrix degradation by mouse embryos. Biol. Reprod. 2001, 64:1331-1337.
27. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5:2145-2154.
28. Zeng B., Ren X., Lin G., Zhu C., Chen H., Yin J., Jiang H., Yang B., Ding D. Paracrine action of HO-1-modified mesenchymal stem cells mediates cardiac protection and functional improvement. Cell Biol. Int. 2008, 32:1256-1264.
29. Zeng B., Chen H., Zhu C., Ren X., Lin G., Cao F. Effects of combined mesenchymal stem cells and heme oxygenase-1 therapy on cardiac performance. Eur. J. Cardiothorac. Surg. 2008, 34:850-856.